These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 20092080)

  • 1. What's new in trial design: propensity scores, equivalence, and non-inferiority.
    Myles PS
    J Extra Corpor Technol; 2009 Dec; 41(4):P6-10. PubMed ID: 20092080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishing equivalence or non-inferiority in clinical trials: part 20 of a series on evaluation of scientific publications.
    Wellek S; Blettner M
    Dtsch Arztebl Int; 2012 Oct; 109(41):674-9. PubMed ID: 23264808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Methodology for superiority versus equivalence and non-inferior clinical studies. A practical review].
    Rosas-Peralta M; Santos-Martínez LE; Magaña-Serrano JA; Valencia-Sánchez JS; Garrido-Garduño M; Pérez-Rodríguez G
    Rev Med Inst Mex Seguro Soc; 2016; 54(3):344-53. PubMed ID: 27100981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple comparisons in non-inferiority trials: Reaction to recent regulatory guidance on multiple endpoints in clinical trials.
    Wiens BL
    J Biopharm Stat; 2018; 28(1):52-62. PubMed ID: 29065276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Methodological and statistical aspects of equivalence and non inferiority trials].
    Elie C; De Rycke Y; Jais JP; Marion-Gallois R; Landais P
    Rev Epidemiol Sante Publique; 2008 Aug; 56(4):267-77. PubMed ID: 18703296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Missing data handling in non-inferiority and equivalence trials: A systematic review.
    Rabe BA; Day S; Fiero MH; Bell ML
    Pharm Stat; 2018 Sep; 17(5):477-488. PubMed ID: 29797777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indications for propensity scores and review of their use in pharmacoepidemiology.
    Glynn RJ; Schneeweiss S; Stürmer T
    Basic Clin Pharmacol Toxicol; 2006 Mar; 98(3):253-9. PubMed ID: 16611199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endpoints in respiratory diseases.
    de Benedictis FM; Guidi R; Carraro S; Baraldi E;
    Eur J Clin Pharmacol; 2011 May; 67 Suppl 1():49-59. PubMed ID: 21104409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The limitations of small outcome studies.
    Gibbons RJ; Hodge D
    J Nucl Cardiol; 2012 Apr; 19(2):230-2. PubMed ID: 22359226
    [No Abstract]   [Full Text] [Related]  

  • 11. Multiple analyses in clinical trials: sound science or data dredging?
    Lord SJ; Gebski VJ; Keech AC
    Med J Aust; 2004 Oct; 181(8):452-4. PubMed ID: 15487966
    [No Abstract]   [Full Text] [Related]  

  • 12. Unplanned adaptations before breaking the blind.
    Posch M; Proschan MA
    Stat Med; 2012 Dec; 31(30):4146-53. PubMed ID: 22736397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayes factors for superiority, non-inferiority, and equivalence designs.
    van Ravenzwaaij D; Monden R; Tendeiro JN; Ioannidis JPA
    BMC Med Res Methodol; 2019 Mar; 19(1):71. PubMed ID: 30925900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re-formulating non-inferiority trials as superiority trials: The case of binary outcomes.
    Durkalski VL; Berger VW
    Biom J; 2009 Feb; 51(1):185-92. PubMed ID: 19197960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical issues in equivalence trials.
    Ebbutt AF; Frith L
    Stat Med; 1998 Aug 15-30; 17(15-16):1691-701. PubMed ID: 9749440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical guide to sample size calculations: non-inferiority and equivalence trials.
    Flight L; Julious SA
    Pharm Stat; 2016; 15(1):80-9. PubMed ID: 26604186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
    Eaton A; Therneau T; Le-Rademacher J
    Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing sample size by combining superiority and non-inferiority for two primary endpoints in the Social Fitness study.
    Donkers H; Graff M; Vernooij-Dassen M; Nijhuis-van der Sanden M; Teerenstra S
    J Clin Epidemiol; 2017 Jan; 81():86-95. PubMed ID: 27650383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-inferiority trials using a surrogate marker as the primary endpoint: An increasing phenotype in cardiovascular trials.
    Bikdeli B; Caraballo C; Welsh J; Ross JS; Kaul S; Stone GW; Krumholz HM
    Clin Trials; 2020 Dec; 17(6):723-728. PubMed ID: 32838556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.